Astria Therapeutics to Present at EADV Congress
Astria Therapeutics, Inc. (NASDAQ: ATXS), an innovative biopharmaceutical firm, is thrilled to share its plans to participate in the esteemed European Academy of Dermatology and Venereology (EADV) Congress. This notable event will be held in Amsterdam, where fresh ideas and cutting-edge research come together.
Presentation Details
This important congress is set for September 26, 2024, during which Astria Therapeutics will present early data from their ALPHA-STAR study. This trial plays a crucial role in examining the safety and effectiveness of navenibart (STAR-0215), a treatment specifically aimed at managing hereditary angioedema.
The Role of Dr. Raffi Tachdjian
Dr. Raffi Tachdjian, an esteemed Associate Clinical Professor of Medicine and Pediatrics with a focus on Allergy and Clinical Immunology at UCLA, will lead the presentation. He’ll share key findings from the Phase 1b/2 clinical trial in his poster titled, “ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes.”
A Deep Dive into ALPHA-STAR Data
The poster presentation is scheduled for the e-poster showcase session on the afternoon of September 26, offering attendees a chance to explore initial results related to the safety and efficacy of STAR-0215. This trial is designed to enhance our understanding of possible treatments for patients struggling with hereditary angioedema.
About Astria Therapeutics
Astria Therapeutics is committed to changing the lives of patients and families affected by allergic and immunologic diseases. Their leading program, navenibart (STAR-0215), is making strides in clinical trials as a monoclonal antibody that targets plasma kallikrein. This innovative strategy is expected to significantly improve the management of hereditary angioedema.
Innovative Therapeutics in Development
Alongside STAR-0215, the company is also working on STAR-0310, another monoclonal antibody designed to block OX40. This program is currently in its preclinical phases, focusing on the treatment of atopic dermatitis. Astria Therapeutics remains dedicated to addressing the urgent needs of those affected by these conditions.
Join Us in Amsterdam
We invite anyone interested in dermatology and therapeutic advancements to attend the EADV Congress. The insights shared by Dr. Tachdjian and other key figures in the field promise to offer valuable knowledge for professionals and stakeholders alike.
Frequently Asked Questions
What is the EADV Congress?
The EADV Congress is a major event that highlights the latest advancements in dermatology, attracting researchers and clinicians from across the globe.
Who will present at the congress?
Dr. Raffi Tachdjian from UCLA will deliver a presentation on important findings regarding navenibart during the event.
What is navenibart?
Navenibart (STAR-0215) is a monoclonal antibody currently being studied for its effectiveness in treating hereditary angioedema.
What is hereditary angioedema?
Hereditary angioedema is a genetic disorder that results in recurrent episodes of severe swelling in various areas of the body.
Can I learn more about Astria Therapeutics?
Absolutely! You can find additional information about the company and its groundbreaking therapies by visiting their official website.